{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:59:23Z","timestamp":1791057563266,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/ajg.2009.749","type":"journal-article","created":{"date-parts":[[2010,1,19]],"date-time":"2010-01-19T10:55:33Z","timestamp":1263898533000},"page":"1595-1603","source":"Crossref","is-referenced-by-count":61,"title":["Topical Rosiglitazone Treatment Improves Ulcerative Colitis by Restoring Peroxisome Proliferator-Activated Receptor-\u03b3 Activity"],"prefix":"10.14309","volume":"105","author":[{"given":"Gitte","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Brynskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20210210","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gut.2006.093484","article-title":"PPAR as a new therapeutic target in inflammatory bowel diseases.","volume":"55","author":"Dubuquoy","year":"2006","journal-title":"Gut"},{"key":"R2-24-20210210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s000110050622","article-title":"Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.","volume":"49","author":"Chinetti","year":"2000","journal-title":"Inflamm Res"},{"key":"R3-24-20210210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1152\/physiolgenomics.00042.2007","article-title":"Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon.","volume":"30","author":"Su","year":"2007","journal-title":"Physiol Genomics"},{"key":"R4-24-20210210","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bcp.2007.05.027","article-title":"13-Oxo-ODE is an endogenous ligand for PPAR in human colonic epithelial cells.","volume":"74","author":"Altmann","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"R5-24-20210210","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1073\/pnas.1031789100","article-title":"PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN- target genes in macrophages.","volume":"100","author":"Welch","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-24-20210210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR- agonists inhibit production of monocyte inflammatory cytokines.","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"R7-24-20210210","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1053\/j.gastro.2007.02.032","article-title":"The role of PPAR on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction.","volume":"132","author":"Ponferrada","year":"2007","journal-title":"Gastroenterology"},{"key":"R8-24-20210210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation.","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"R9-24-20210210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.193.7.827","article-title":"Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)peroxisome proliferator-activated receptor (PPAR) heterodimer. A basis for new therapeutic strategies.","volume":"193","author":"Desreumaux","year":"2001","journal-title":"J Exp Med"},{"key":"R10-24-20210210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00054725-200209000-00004","article-title":"Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.","volume":"8","author":"Saubermann","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"R11-24-20210210","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/gut.2005.081745","article-title":"Peroxisome proliferator activated receptor in colonic epithelial cells protects against experimental inflammatory bowel disease.","volume":"55","author":"Adachi","year":"2006","journal-title":"Gut"},{"key":"R12-24-20210210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2007.12.188","article-title":"4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor agonist alleviates the symptoms of DSS-induced colitis.","volume":"367","author":"Yamamoto","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"R13-24-20210210","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0016-5085(03)00262-2","article-title":"A novel PPAR gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.","volume":"124","author":"Katayama","year":"2003","journal-title":"Gastroenterology"},{"key":"R14-24-20210210","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10875-007-9074-2","article-title":"The PPAR agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis.","volume":"27","author":"Ramakers","year":"2007","journal-title":"J Clin Immunol"},{"key":"R15-24-20210210","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0016-5085(03)00271-3","article-title":"Impaired expression of peroxisome proliferator-activated receptor in ulcerative colitis.","volume":"124","author":"Dubuquoy","year":"2003","journal-title":"Gastroenterology"},{"key":"R16-24-20210210","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/S0016-5085(03)00345-7","article-title":"Is there a role for PPAR in IBD? Yes, no, maybe.","volume":"124","author":"Wu","year":"2003","journal-title":"Gastroenterology"},{"key":"R17-24-20210210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/j.gastro.2007.12.012","article-title":"Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.","volume":"134","author":"Lewis","year":"2008","journal-title":"Gastroenterology"},{"key":"R18-24-20210210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3748\/wjg.14.114","article-title":"A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.","volume":"14","author":"Liang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R19-24-20210210","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R20-24-20210210","first-page":"1520","article-title":"Rosiglitazone no longer recommended.","volume":"372","year":"2009","journal-title":"Lancet"},{"key":"R21-24-20210210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0016-5085(94)90054-X","article-title":"Course of ulcerative colitis: analysis of changes in disease activity over years.","volume":"107","author":"Langholz","year":"1994","journal-title":"Gastroenterology"},{"key":"R22-24-20210210","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/003655200750023471","article-title":"A simple method to establish short-term cultures of normal human colonic epithelial cells from endoscopic biopsy specimens. Comparison of isolation methods, assessment of viability and metabolic activity.","volume":"35","author":"Pedersen","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"R23-24-20210210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/gut.51.1.37","article-title":"Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease.","volume":"51","author":"Brynskov","year":"2002","journal-title":"Gut"},{"key":"R24-24-20210210","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1093\/nar\/19.14.3998","article-title":"36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO.","volume":"19","author":"Laborda","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"R25-24-20210210","doi-asserted-by":"crossref","first-page":"29681","DOI":"10.1074\/jbc.M103779200","article-title":"Target genes of peroxisome proliferator-activated receptor in colorectal cancer cells.","volume":"276","author":"Gupta","year":"2001","journal-title":"J Biol Chem"},{"key":"R26-24-20210210","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/00365520410009573","article-title":"Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas.","volume":"40","author":"Matthiessen","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"R27-24-20210210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/08916930008994099","article-title":"Cultures of human colonic epithelial cells isolated from endoscopical biopsies from patients with inflammatory bowel disease. Effect of IFN, TNF and IL-1 on viability, butyrate oxidation and IL-8 secretion.","volume":"32","author":"Pedersen","year":"2000","journal-title":"Autoimmunity"},{"key":"R28-24-20210210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.","volume":"132","author":"DHaens","year":"2007","journal-title":"Gastroenterology"},{"key":"R29-24-20210210","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"R30-24-20210210","doi-asserted-by":"crossref","first-page":"G266","DOI":"10.1152\/ajpgi.00486.2001","article-title":"Controversy: PPAR as a target for treatment of colorectal cancer.","volume":"283","author":"Gupta","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R31-24-20210210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.52.2.231","article-title":"Superoxide production and expression of NAD(P)H oxidases by transformed and primary human colonic epithelial cells.","volume":"52","author":"Perner","year":"2003","journal-title":"Gut"},{"key":"R32-24-20210210","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2249.2005.02848.x","article-title":"Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.","volume":"141","author":"Pedersen","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R33-24-20210210","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/2036","article-title":"Activation of the peroxisome proliferator-activated receptor promotes the development of colon tumors in C57BL6J-APCMin mice.","volume":"4","author":"Lefebvre","year":"1998","journal-title":"Nat Med"},{"key":"R34-24-20210210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1677\/joe.0.1620331","article-title":"Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells.","volume":"162","author":"Lefebvre","year":"1999","journal-title":"J Endocrinol"},{"key":"R35-24-20210210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1083\/jcb.200809028","article-title":"Regulation of epithelial- mecenchymal IL-1 signaling by PPAR is essential for skin homeostasis and wound healing.","volume":"184","author":"Chong","year":"2009","journal-title":"J Cell Biol"},{"key":"R36-24-20210210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1471-4914(01)02076-7","article-title":"PPAR and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohns disease.","volume":"7","author":"Wada","year":"2001","journal-title":"Trends Mol Med"},{"key":"R37-24-20210210","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s001250051218","article-title":"Downregulation of peroxisome proliferator-activated receptor expression by inflammatory cytokines and its reversal by thiazolidinediones.","volume":"42","author":"Tanaka","year":"1999","journal-title":"Diabetologia"},{"key":"R38-24-20210210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.metabol.2006.10.007","article-title":"Tumor necrosis factor and interleukin 1 decrease RXR, PPAR, PPAR, LXR, and the coactivators SRC-1, PGC-1, and PGC-1 in liver cells.","volume":"56","author":"Kim","year":"2007","journal-title":"Metabolism"},{"key":"R39-24-20210210","doi-asserted-by":"crossref","first-page":"G722","DOI":"10.1152\/ajpgi.00411.2003","article-title":"Tumor necrosis factor- inhibits peroxisome proliferator-activated receptor activity at a posttranslational level in hepatic stellate cells.","volume":"286","author":"Sung","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R40-24-20210210","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.1074\/jbc.M007894200","article-title":"Interferon--induced regulation of peroxisome proliferator-activated receptor and STATs in adipocytes.","volume":"276","author":"Waite","year":"2001","journal-title":"J Biol Chem"},{"key":"R41-24-20210210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohns disease.","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"R42-24-20210210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/gut.33.1.55","article-title":"Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease.","volume":"33","author":"Brynskov","year":"1992","journal-title":"Gut"},{"key":"R43-24-20210210","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.mib.0000231496.92013.85","article-title":"Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.","volume":"12","author":"Regueiro","year":"2006","journal-title":"Inflamm Bowel Dis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2009749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2009749","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2009749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201007000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:59Z","timestamp":1786542419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201007000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2009.749","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}